Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you.
Email Address *
First Name
Mailing Lists *

BCLI: Additional Manufacturing Facility Secured for Phase 3 ALS Trial

By David Bautz, PhD



Business Update

Additional Manufacturing Facility for Phase 3 Trial

On July 2, 2018, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute will serve as a second manufacturing facility to supply NurOwn® for the company’s ongoing Phase 3 clinical trial in amyotrophic lateral sclerosis (ALS). Dana Farber was previously used as a manufacturing facility of NurOwn® in the Phase 2 trial. In addition to supplying NurOwn® for the ongoing Phase 3 trial, we believe the facility will likely be used to manufacture NurOwn® for any additional clinical indications the company decides to pursue.

DSMB Meeting in August 2018

The first meeting of the Phase 3 Data Safety and Monitoring Board (DSMB) is expected to take place in August 2018. With some patients having already received multiple doses of NurOwn®, this should give an early indication as to the tolerability of repeat dosing, however we do not anticipate there being any safety issues.

Executive Management Team Strengthened

BrainStorm recently announced the expansion of its executive management team with seasoned veterans that will add valuable experience as the company moves closer to finishing up the Phase 3 trial and potential commercialization stage.

‣ Susan Ward, PhD has been hired as Head of Clinical Operations. Dr. Ward previously served as Director, Early Clinical Development at Pfizer and has more than 20 years of experience in various leadership positions involving clinical trials, IND-enabling studies, and protocol development.

‣ Joseph Petroziello has been hired as Vice President of Scientific & Corporate Communications. He previously served as Senior Director/Head of Scientific Communications & Publications at Juno Therapeutics. Mr. Petroziello as over 20 years of medical writing, scientific communication, and drug research experience.

Financial Update

We have heard from some investors recently that were concerned about the $100 million S-3 filing in June 2018 and if that meant the company was planning on raising capital soon. We spoke to management about this and were told that the S-3 was filed due to the fact that the prior S-3 was expiring, that it is simply a way for the company to maintain flexibility, and there is no intention of using it to raise funds at this time. In addition, one of the clauses of the recent warrant exchange stipulates that no financings can occur within 90 days of the warrant exchange. We estimate that BrainStorm exited the second quarter of 2018 with approximately $17-$18 million in cash and cash equivalents, with another approximately $9 million left from the CIRM grant that is helping to fund the Phase 3 clinical trial. Thus, we don’t see an imminent financing as a possibility at this time.


BrainStorm is continuing to enroll patients in the Phase 3 ALS trial at a good pace and we are glad to see the addition of another manufacturing facility to ensure that continues. While we are uncertain if this will allow enrollment in the trial to increase, it’s something that we will be watching closely in the next few months. We still anticipate topline data from the study toward the end of 2019/early 2020. Our valuation remains at $15.
User ID:
Remember my ID: